Key Points

  1. Rameda Pharmaceuticals' sales to government tenders declined by 63% to EGP 89 million in Q3 2026.
  2. The decline was driven by a 64% decrease in sales volume to 3.1 million units.
  3. Exports grew by 10% to EGP 68 million in Q3 2026, driven by strong demand in Afghanistan and Iraq.

Rameda's Sales Decline and Export Growth

Rameda Pharmaceuticals, an Egyptian pharmaceuticals manufacturer, reported a 63% decline in sales to government tenders to EGP 89 million in Q3 2026. This decline was driven by a 64% decrease in sales volume to 3.1 million units. In contrast, exports grew by 10% to EGP 68 million in Q3 2026, driven by strong demand in Afghanistan and Iraq.

The company attributed this growth to its strong performance in the Afghan market, where sales increased to EGP 23 million, up from less than EGP 1 million in Q3 2025. Additionally, Rameda reported increased sales in Iraq and expansion into new markets, including the UAE and Azerbaijan.

At a Glance

Main CompanyRameda Pharmaceuticals
Egyptian pharmaceuticals manufacturer
Main ExecutiveNot specified
No executive mentioned in the article
OrganizationEgyptian Ministry of Health
Government agency responsible for healthcare
RegulatorEgyptian Unified Procurement Authority (UPA)
Government agency responsible for public procurement
LocationEgypt
Country of operation
CountryEgypt
Country of operation
IndustryPharmaceuticals
Industry sector
Key Product/ServicePharmaceuticals
Main product/service offered by Rameda
Key Financial FigureEGP 89 million
Decline in government tenders sales
Key DateQ3 2026
Quarter under review

Behind Rameda's Q3 2026 Performance

Behind Rameda's Q3 2026 Performance

The decline in government tenders sales was a significant factor in Rameda's Q3 2026 performance. However, the company's exports growth was driven by strong demand in key markets, including Afghanistan and Iraq.

Rameda's performance in these markets was attributed to the company's strong product offerings and its ability to adapt to changing market conditions.

What This Means for Investors and Competitors

What This Means for Investors and Competitors

For investors, Rameda's decline in government tenders sales is a concern, as it may impact the company's revenue growth. However, the company's exports growth is a positive sign, indicating its ability to adapt to changing market conditions.

For competitors, Rameda's performance in key markets, including Afghanistan and Iraq, is a challenge, as it may impact their market share.